Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins FLT3 G697R |
| Therapy | Quizartinib |
| Indication/Tumor Type | hematologic cancer |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 G697R | hematologic cancer | resistant | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed hematologic cells expressing a FLT3-ITD mutation and FLT3 G697R were resistant to Vanflyta (quizartinib) in culture (PMID: 22875611). | 22875611 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22875611) | The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. | Full reference... |